CenterBook Partners’s Krystal Biotech KRYS Stock Holding History

CenterBook Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,429	Closed	-$605K	–	625
2025 Q3	$605K	Sell	3,429 -1,622	-32%	-$243K	0.03%	445
2025 Q2	$694K	Buy	+5,051	New	+$742K	0.04%	383
2025 Q1	–	Sell	-4,283	Closed	-$671K	–	544
2024 Q4	$671K	Buy	+4,283	New	+$760K	0.04%	385
2024 Q1	–	Sell	-5,335	Closed	-$662K	–	440
2023 Q4	$662K	Buy	5,335 +1,020	+24%	+$113K	0.08%	298
2023 Q3	$501K	Buy	+4,315	New	+$526K	0.06%	325

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CenterBook Partners's KRYS Position: Q4 2025 in Review

CenterBook Partners sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 3,429 shares — an estimated $605K sold.

CenterBook Partners first reported a position in KRYS in Q3 2023 and held it in 5 quarters. The position peaked at $694K in Q2 2025. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

CenterBook Partners reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
CenterBook Partners sold 3,429 Krystal Biotech shares in Q4 2025, an estimated $605K.
CenterBook Partners first reported a position in Krystal Biotech in Q3 2023 and held it in 5 quarters.
CenterBook Partners's Krystal Biotech position peaked at $694K in Q2 2025.
334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on CenterBook Partners's 13F filing for Q4 2025, filed 11 Feb 2026.